Trial Profile
SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary) ; Docetaxel; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAPROCAN
- 13 Feb 2021 Results assessing safety and efficacy of saracatinib (AZD0530) and docetaxel in patients with metastatic castrate-refractory prostate cancer, presented at the 2021 Genitourinary Cancers Symposium.
- 16 May 2016 Status changed from recruiting to completed.
- 11 Dec 2015 Accrual to date is 89% according to the United Kingdom Clinical Research Network record.